Long term palliation of a metastatic primary gliosarcoma with stereotactic body radiotherapy

Janaki Manur Gururajachar, Sweta Polisetty


Primary gliosarcoma (PGS) is rare and is known for extra cranial metastases. The overall outcome is dismal and hence the focus is on providing the best quality of life. This report describes a seventy-year-old lady who at presentation had metastatic primary gliosarcoma with intractable cough. Her lung lesion was treated with stereotactic body radiotherapy (SBRT) to a dose of 10 Gy per fraction for three consecutive days. She was free of cough till her death at eighteen months after treatment. This is probably the first reported case of excellent long-term quality of life in a patient of metastatic primary gliosarcoma.


Gliosarcoma, Lung Metastases, SBRT

Full Text:



Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: Epidemiology, naturalhistory, and factors associated with outcome. Neuro Oncol. 2009;11:183-91.

Andaloussi-Saghir K, Oukabli M, El Marjany M, et al. Secondary gliosarcoma after the treatment of primary glioblastoma multiforme. N Am J Med Sci. 2011;3:527-30.

Ryan CM, Arie P. Glioblastoma: Morphologic and molecular genetic diversity. Arch Pathol Lab Med. 2007; 131:397-406.

Beaumont TL, Kupsky WJ, Barger GR, Sloan AE. Gliosarcoma with multiple extracranial metastases: Case report and review of the literature. J Neurooncol. 2007;83:39-46.

Han SJ, Yang I, Tihan T, et al. Primary gliosarcoma: Key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol. 2010;96:313-20.

Kumar P, Singh S, Kumar P, et al. Gliosarcoma: An audit from a single institution in India of 24 post-irradiated cases over 15 years. J Cancer Res Ther. 2008;4:164-8.

Stragliotto CL, Karlsson K, Lax I, et al. A retrospective study of SBRT of metastases in patients with primary sarcoma. Med Oncol. 2012;29:3431-9.

DOI: http://dx.doi.org/10.14319/ijcto.41.4

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013